Combination of GD2-directed bispecific trifunctional antibody therapy with Pd-1 immune checkpoint blockade induces anti-neuroblastoma immunity in a syngeneic mouse model

INTRODUCTION: Despite advances in treating high-risk neuroblastoma, 50-60% of patients still suffer relapse, necessitating new treatment options. Bispecific trifunctional antibodies (trAbs) are a promising new class of immunotherapy. TrAbs are heterodimeric IgG-like molecules that bind CD3 and a tum...

Descripción completa

Detalles Bibliográficos
Autores principales: Ivasko, Sara Marie, Anders, Kathleen, Grunewald, Laura, Launspach, Michael, Klaus, Anika, Schwiebert, Silke, Ruf, Peter, Lindhofer, Horst, Lode, Holger N., Andersch, Lena, Schulte, Johannes H., Eggert, Angelika, Hundsdoerfer, Patrick, Künkele, Annette, Zirngibl, Felix
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9869131/
https://www.ncbi.nlm.nih.gov/pubmed/36700232
http://dx.doi.org/10.3389/fimmu.2022.1023206

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9869131/
https://www.ncbi.nlm.nih.gov/pubmed/36700232
http://dx.doi.org/10.3389/fimmu.2022.1023206

Ejemplares similares